Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003293 · ClinicalTrials.gov registry record · Phase 3
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
A Phase 3 study of Brain and Central Nervous System Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00003293: Completed Phase 3 study of Brain and Central Nervous System Tumors, sponsored by Pfizer.
NCT00003293 is a Phase 3 study of Brain and Central Nervous System Tumors that has completed, run by Pfizer. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003293, a Phase 3 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of SU-101 with that of procarbazine in treating patients with glioblastoma multiforme that has recurred.
Conditions Studied
Interventions
- DRUG leflunomide
- DRUG procarbazine hydrochloride
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Beckman Research Institute, City of Hope - Los Angeles
- St. Francis Hospital - San Francisco
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Arizona Cancer Center - Tucson
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Hospital - Detroit
New York
- Cancer Center of Albany Medical Center - Albany
- Memorial Sloan-Kettering Cancer Center - New York
Colorado
- University of Colorado Cancer Center - Denver
Georgia
- Medical College of Georgia Hospital and Clinics - Augusta
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-02 |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
What the finished NCT00003293 record still lists
NCT00003293 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which leflunomide is the first listed.
NCT00003293 names 20 study sites across 12 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00003293 about?
NCT00003293 is a clinical study titled "SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effect...
What is the current status of trial NCT00003293?
This trial is currently completed. It is a Phase 3 study. The study started on 1998-02. Estimated completion is 2001-05.
What conditions does trial NCT00003293 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003293?
The interventions under investigation include: leflunomide (DRUG), procarbazine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003293?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003293 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
COMPLETED · Phase 3
-
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia